Holen Sie sich die Stockscreener-App
5.96
0.51%
0.03
Handel nachbörslich:
5.85
-0.11
-1.85%
Schlusskurs vom Vortag:
$5.93
Offen:
$5.87
24-Stunden-Volumen:
913.13K
Relative Volume:
0.65
Marktkapitalisierung:
$827.94M
Einnahmen:
$62.04M
Nettoeinkommen (Verlust:
$-533.34M
KGV:
-1.5204
EPS:
-3.92
Netto-Cashflow:
$-473.07M
1W Leistung:
-0.33%
1M Leistung:
+4.38%
6M Leistung:
-2.61%
1J Leistung:
-20.43%
1-Tages-Spanne:
$5.76
$5.98
1-Wochen-Bereich:
$5.76
$6.555
52-Wochen-Spanne:
$4.155
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
Firmenname
Vir Biotechnology Inc
Sektor
Branche
Telefon
415-906-4324
Adresse
1800 OWENS STREET, SAN FRANCISCO, CA
Vergleichen Sie VIR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
5.96 | 823.77M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Eingeleitet | Evercore ISI | Outperform |
| 2025-08-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-03-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Eingeleitet | SVB Leerink | Outperform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-03-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-01-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-09-14 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-11 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Eingeleitet | Needham | Buy |
| 2020-03-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2020-02-27 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2019-11-05 | Eingeleitet | Barclays | Overweight |
| 2019-11-05 | Eingeleitet | Cowen | Outperform |
| 2019-11-05 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten
Why Vir Biotechnology Inc. stock remains on watchlistsWeekly Risk Summary & Reliable Volume Spike Trade Alerts - newser.com
Best data tools to analyze Vir Biotechnology Inc. stockMarket Sentiment Report & AI Forecast for Swing Trade Picks - newser.com
Vir Biotechnology Hits Day Low of $5.87 Amid Price Pressure - Markets Mojo
Pattern recognition hints at Vir Biotechnology Inc. upside2025 Earnings Impact & Short-Term Trading Opportunity Alerts - newser.com
Top chart patterns to watch in Vir Biotechnology Inc.July 2025 PostEarnings & Reliable Price Breakout Alerts - newser.com
Why Vir Biotechnology Inc. stock is favored by top institutions2025 Big Picture & Real-Time Chart Breakout Alerts - newser.com
Vir Biotechnology Inc. stock trendline breakdownJuly 2025 Macro Moves & Real-Time Buy Zone Alerts - newser.com
What analysts say about Vir Biotechnology Inc stockHigh Beta Stocks & Market Analysis Tools You Can Trust - earlytimes.in
Is Vir Biotechnology Inc. forming a reversal patternAnalyst Upgrade & Free Real-Time Market Sentiment Alerts - newser.com
Is now a turning point for Vir Biotechnology Inc.Stock Surge & Real-Time Market Sentiment Alerts - newser.com
Can technical indicators confirm Vir Biotechnology Inc.’s reversal2025 Volatility Report & Proven Capital Preservation Tips - newser.com
How to escape a deep drawdown in Vir Biotechnology Inc.July 2025 Fed Impact & Expert Approved Momentum Trade Ideas - newser.com
Will Vir Biotechnology Inc. stock deliver consistent dividendsWeekly Loss Report & Weekly Watchlist of Top Performers - newser.com
Tools to monitor Vir Biotechnology Inc. recovery probabilityTrend Reversal & Expert Verified Stock Movement Alerts - newser.com
Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 24,453 Shares - MarketBeat
Vir Biotechnology’s Phase 1 Study on VIR-5525: A Potential Game-Changer in Cancer Treatment? - MSN
How Vir Biotechnology Inc. stock reacts to inflationary pressuresWeekly Stock Report & Fast Gaining Stock Reports - newser.com
What the charts say about Vir Biotechnology Inc. todayJuly 2025 Update & Fast Exit Strategy with Risk Control - newser.com
Risk adjusted return profile for Vir Biotechnology Inc. analyzedTake Profit & Daily Profit Focused Stock Screening - newser.com
Vir Biotechnology Form 4: 10b5-1 sales; 14,573,983 shares remain - Stock Titan
Vir Biotechnology’s Hepatic Impairment Study: A Potential Game Changer? - MSN
Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 46,696 Shares - MarketBeat
Endurance (Cayman) Ltd Svf Sells 66,403 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Vir Biotechnology, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
VIR insider filing shows October sales under 10b5‑1 plan - Stock Titan
With 59% ownership, Vir Biotechnology, Inc. (NASDAQ:VIR) boasts of strong institutional backing - Yahoo Finance
How buybacks impact Vir Biotechnology Inc. stock value2025 Geopolitical Influence & Weekly High Return Stock Opportunities - fcp.pa.gov.br
Published on: 2025-10-27 20:00:38 - newser.com
Finanzdaten der Vir Biotechnology Inc-Aktie (VIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.62%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):